Persistent Asset Partners Ltd Acquires Shares of 9,433 Enliven Therapeutics, Inc. $ELVN

Persistent Asset Partners Ltd acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 9,433 shares of the company’s stock, valued at approximately $479,000.

Several other hedge funds have also recently modified their holdings of the stock. KBC Group NV purchased a new position in Enliven Therapeutics during the first quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Enliven Therapeutics in the 4th quarter worth $83,000. Finally, Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $58.82 on Monday. The firm has a fifty day simple moving average of $50.90 and a two-hundred day simple moving average of $40.90. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32. The stock has a market capitalization of $4.31 billion, a P/E ratio of -35.22 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ELVN. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. The Goldman Sachs Group increased their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Stifel Nicolaus lifted their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, HC Wainwright upped their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $72.67.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total value of $316,787.52. Following the completion of the transaction, the chief financial officer owned 46,054 shares in the company, valued at approximately $2,424,282.56. The trade was a 11.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director directly owned 41,884 shares in the company, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 190,831 shares of company stock valued at $10,991,723 over the last ninety days. 3.00% of the stock is owned by insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.